Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
Feb 11, 2025 | Benefits Advisory Conference, Benefits management, Caroline Fraker, Compliance, Forensic claims review, MedBen University, No Surprises Act (NSA), Pharmacy, Stop-Loss, Wellness
Over 70 guests from seven states attended the MedBen 2025 Benefits Advisory Conference on January 30. Featuring some of the most respected names in the industry, this invitation-only event provided brokers with an extensive look at the state of benefits...
Oct 28, 2024 | Federal Trade Commission (FTC), Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Spread Pricing
KFF Health News reports on the disparity between pharmacy benefit manager (PBM) payments to large pharmacy chains compared to small drugstores: “[An American Pharmacy Cooperative] analysis early this year showed chains were paid well beyond the family business...
Oct 1, 2024 | Genomics, Kurt Harden, MedBen News, Nutrigenomics, Pharmacogenomics, Pharmacy, Wellness
MedBen Chairman & CEO Kurt Harden and Profero Team Director of Precision Medicine Cynthia Yu were featured presenters at the 11th Annual Sherrill-Morgan Healthcare Innovation Conference on September 18th. Harden and Yu spoke on the topic of genomic testing — what...
Sep 27, 2024 | Drug advertising, Drug costs, Pharmacy, Rebates, Study
KFF Health News warns consumers not to take TV drug ads at face value: “A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. ‘I worry that...
Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
